About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, February 6th, 2018

The QualityStocks
Daily Stock List


CLS Holdings USA, Inc. (CLSH)

HotStockProfits, Beacon Equity Research, InvestorSoup, Penny Stock Craze, Penny Stocks Finder, Stock Preacher, SuperStockTips, Fortune Stock Alerts, MoneyTV, Stock Commander, Equity Observer, Value Penny Stocks, eliteotc, SMS Penny Picks, Wall Street Beauties, WINNINGOTC, SmallCapAllStars, TryBestPennyStocks.biz, Penny Stock Professor, PennyPickAlerts, and Traders350 reported on CLS Holdings USA, Inc. (CLSH), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

CLS Holdings USA, Inc. is a development stage diversified cannabis company. CLS stands for "Cannabis Life Sciences," in recognition of its patent pending proprietary method of extracting different cannabinoids from the marijuana plant and converting them into a higher quality and quantity of products. CLS Holdings USA specializes in the extraction and conversion of cannabinoids. It is shifting its strategy to becoming a fully licensed integrated cannabis producer and retailer in Nevada and other western states. CLS Holdings USA is based in Boulder, Colorado.

The Company’s business model includes licensing operations, processing revenue, processing facilities, sale of products, brand creation, as well as consulting services. Its corporate mission is to be the industry leader in the extraction, conversion and marketing of cannabinoid oils, wax, edibles, and shatter through leveraging its proprietary extraction methods and conversion processes.

CLS Labs took its initial step toward commercializing its proprietary methods and processes through entering into an arrangement in Colorado on April 17, 2015. It entered into an arrangement by way of CLS Labs Colorado to, among other things, license its proprietary technology, methods, and processes to PRH in exchange for a fee; and construct a processing facility and lease such facility, including equipment, to PRH.

CLS will agree to build out a processing facility and then lease the facility and equipment to the client for what will typically be a 10-year term. The client will be required to enter into an agreement of equal length to license CLS’s proprietary technology, methods, and processes solely for use in the processing facility.

CLS’s plan is to monetize the extraction method and generate revenues via the licensing of its proprietary methods and processes to others, as in the Colorado Arrangement, the processing of cannabis for others, and the purchase of cannabis and the processing and sale of cannabis-related products.

CLS Holdings USA announced in June of 2017 that it entered into a non-binding Letter of Intent (LOI) with privately owned Pure Harvest Cannabis Producers, Inc. of Las Vegas, Nevada. Pure Harvest is a science-based medical cannabis business. Its plan is to become a licensed vertically integrated cannabis business engaged in all aspects of the cannabis cycle. The expectation is that upon closing CLS Holdings will relocate to Las Vegas and change its name to "Pure Harvest Cannabis Group, Inc."

This past December, CLS Holdings announced that it entered into a definitive agreement to acquire Oasis Cannabis. Oasis has established itself as one of the foremost marijuana retailers in Nevada, offering in-store and delivery service to its customers. Oasis is a fully-integrated company. It provides grow, extraction, and conversion services, complete with a retail dispensary business.

The Oasis conversion and extraction facility produced $200,000 in Gross Revenues in December 2017, its strongest result so far since commencing in mid-2017. Since opening in 2015, Oasis Cannabis has been successfully operating a delivery service to medical patients, and adult-use marijuana to residents since August 2017.

Last month, CLS Holdings USA announced that it received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its proprietary extraction and conversion methodology. The proprietary extraction process differs from others that normally use ethanol, supercritical CO2 or butane. The resulting finished product is cleaner and provides for more Delta 9 THC.

CLS Holdings USA, Inc. (CLSH), closed Tuesday's trading session at $0.8231, up 2.89%, on 6,416 volume with 15 trades. The average volume for the last 60 days is 39,589 and the stock's 52-week low/high is $0.0247/$0.94.

3PEA International, Inc. (TPNL)

The Next Hot Stock, FeedBlitz, HyperSpeedStocks, Volcano Stocks, OtcWizard, and Nebula Stocks reported on 3PEA International, Inc. (TPNL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

3PEA International, Inc. is a vertically integrated provider of unique prepaid card programs and processing services. These are for corporate, consumer, and government applications. By way of its PaySign® brand, the Company designs and develops payment solutions, prepaid card programs, as well as customized payment services. 3PEA International has its corporate office in Henderson, Nevada.

Via the PaySign platform, 3PEA International provides an assortment of services. This includes transaction processing, cardholder enrolment, value loading, cardholder account management, reporting, and customer service.

3PEA’s customers include healthcare companies, major pharmaceutical companies, and source plasma providers. In addition, its customers include large multinationals, prestigious universities, and social media companies.

In essence, 3PEA International is a payment processor and debit card program manager. The Company manages programs for many of the world’s largest pharmaceutical manufacturers with copay assistance products designed to maximize new patient acquisition, retention, and adherence. Its customizable prepaid solutions provide major cost savings. This is while improving brand recognition and customer loyalty.

3PEA International has launched the PaySign® brand of prepaid cards. This includes solutions for corporate incentives, payroll, public sector, pharmaceutical co-pay assistance, source plasma donations, general spend reloadable, and other market niches.

The Company has an increased presence in the plasma donation payments space through signing The Interstate Companies and B Positive National Blood Services. 3PEA also entered into an agreement with Visa, whereby 3PEA exclusively issues Visa-branded prepaid cards for the PaySign® brand.

3PEA has expanded its PaySign® brand of prepaid cards to the automotive market with PaySign Connect for Automobile Dealerships. The wide-ranging PaySign Connect prepaid solution is a customizable, multi-purpose platform tailored to the unique needs of auto dealerships.

For Q3 2017, 3PEA International revenue grew 42 percent to $4.0 million versus $2.8 million in the same prior year quarter. Revenue for the nine months ended September 30, 2017 grew 44 percent to $10.6 million from $7.3 million for the same period the year prior.

Gross profit for Q3 2017 increased to $1.86 million versus $1.30 million in the same prior year quarter. Gross profit for the nine months ended September 30, 2017 rose to $4.78 million from $3.30 million for the same period the year prior.

Q3 Net income was $500,168, or $.01 per share. This is in comparison to net income of $480,429 or $.01 per share in the same prior year quarter. Net income for the nine months ended September 30, 2017 was $1,254,004 or $0.03 per share. This is in comparison to $898,040 or $0.02 per share in the same prior year period.

Earlier this month, 3PEA International announced the addition of Bio/Pharma copay offset and reimbursement industry veteran, Mr. Al Negron, to its Executive Team as Senior Vice President Business Development in charge of 3PEA International’s Healthcare vertical.

Mr. Negron is a veteran of the Bio/Pharmaceutical services industry. He has a record of greater than 25 years of success and achievement in speeding up revenue growth, increasing profitability, and expanding market footprints for his Bio/Pharmaceutical clients.

3PEA International, Inc. (TPNL), closed Tuesday's trading session at $0.76, up 2.70%, on 132,347 volume with 25 trades. The average volume for the last 60 days is 31,544 and the stock's 52-week low/high is $0.35/$0.755.

E-Qure Corp. (EQUR)

OTC Markets and AwesomePennyStocks reported on E-Qure Corp. (EQUR), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

E-Qure Corp. is a leader in medical devices for the treatment of advanced wound care. The Company concentrates on the development and commercialization of Bioelectrical Signal Therapy (BST) devices in the United States. A management team with wide-ranging experience in electrotherapies, medical technologies, wound care, regulatory affairs, as well as finance leads E-Qure.

The Company’s international operations center on managing the processes of design, production, regulation, and distribution of E-Qure’s products and services. Incorporated in 1988, E-Qure has its corporate office in New York, New York.

E-Qure’s BST device employs patented and proprietary electrical stimulation technologies to treat hard-to-cure wounds and ulcers up to complete closure and/or cure. The Company’s BST device lessens treatment and hospitalization time, and reduces the need for surgery and amputation. The BST Device has received regulatory approval in Europe and Israel.

The BST device is a clinically approved non-invasive, painless and user-friendly electrotherapy. The BST device is easily applied by the caregiver or patient in the hospital or clinic setting and in home care.

The BST signal enables the stimulation of sensory nerves and direct stimulation of the ulcer tissues. The nervous system interprets the transmitted pulse from the damaged area. It subsequently begins healing activity to the wound tissues.

The BST device can hasten healing with quick wound closure from 45 to 60 days. Through causing wounds to respond to stimulating signals, the BST device increases the body’s naturally occurring electrical currents to stimulate the wound healing process of Diabetic Wounds; Vascular (Arterial or Venous) Leg Ulcers; Pressure (Decubitus) Wounds; and other Ulcers/Wounds, which are resistant to standard or more complex treatments.

The BST Device activates a healing process that involves Wound Healing - the initiation and expediting of the wound healing process; Pain - reduction of local pain and substantial increase in tissue viability.

In addition, the wound healing process involves Granulation – the regeneration of viable connective tissue; Epithelialisation –the regeneration of viable epithelial tissue; and Vascularisation (angiogenesis) - the regeneration of vital blood vessels.

In February of 2017, E-Qure announced that it received approval from the U.S. Food and Drug Administration (FDA) to conduct its pivotal trial for its patented Bio-electrical Signal Therapy Device (BST Device) in the treatment of chronic wound care as a staged study, potentially shortening the length of the trial.

E-Qure Corp. (EQUR), closed Tuesday's trading session at $0.06, up 9.09%, on 29,300 volume with 3 trades. The average volume for the last 60 days is 11,285 and the stock's 52-week low/high is $0.042/$0.51.

Cannabics Pharmaceuticals, Inc. (CNBX)

Stockgoodies, Promotion Stock Secrets, Cannabis Financial Network News, Market Intelligence Center, Wealth Insider Alert, Wall Street Mover, SmallCapVoice, StreetAuthority Daily, Wall Street Daily, TopPennyStockMovers, and TheMicrocapNews reported previously on Cannabics Pharmaceuticals, Inc. (CNBX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cannabics Pharmaceuticals, Inc.’s devotion is to the development of advanced cannabinoid-based treatments and therapies. Its main emphasis is the development of novel therapies and biotechnological tools designed to provide relief from assorted ailments and treat human malignancies. The Company’s vision is to create individually tailored natural therapies for cancer patients, employing advanced screening systems and personalized bioinformatics tools. OTCQB-listed, Cannabics Pharmaceuticals has its headquarters in Bethesda, Maryland.

Cannabics has licensed Research and Development (R&D) based in Israel. This R&D’s commitment is to the development of palliative and personalized anti-cancer treatments channelling the multipurpose therapeutic values of cannabinoids to create tailored therapies for cancer patients. The Company’s integrated technology has created a successful medically standardized delivery system providing patients natural, reliable, and safe therapy.

Cannabics Pharmaceuticals’ advanced tools include novel delivery systems, personalized medicine diagnostics, and therapies based on cannabinoid compounds. Its chief technology is Cannabics SR. This technology is for a long acting oil capsule, which provides a safe, effective, and reliable administration of cannabis. The technology’s composition is exclusively from food grade materials.

In July 2017, Cannabics Pharmaceuticals announced that it executed a Collaboration Agreement with SIMFO GmbH. Under this Agreement, Cannabics shall be the exclusive worldwide provider of SIMFO's CTC diagnostics to cancer patients treated with natural cannabinoids. SIMFO (located in Germany) is an international leader in cancer diagnostics and liquid biopsies.

Cannabics Pharmaceuticals has established a Genetic lab. This lab will develop diagnostic tools based on human genome, tumor genetics, and cannabinoids.

This past November, Cannabics Pharmaceuticals announced that it filed the first of a cluster of patent applications with the US Patent & Trademark Office (USPTO) that covers their continuing work on the use of cannabinoid products for adjusting the varied microbial populations that live on and in the body.

Furthermore, in November, Cannabics Pharmaceuticals announced that it received a new research license from the Israeli Ministry of Health for the Characterization of anti-tumor activity of cannabinoids. The new license will enable Cannabics to continue its vision of developing an ecosystem for the creation of diagnostic tools and bringing to market diagnostic services for cancer patients who are medicated with cannabis.

Last month, the Company announced that it filed a global patent application with the PCT authorities on methods for testing which cannabinoids or combinations of cannabinoids are likely be effective in individual patients. The determination is made by testing the effects of cannabinoids on CTCs (Circulating Tumor Cells) and biopsies of cancer patients.

Cannabics Pharmaceuticals, Inc. (CNBX), closed Tuesday's trading session at $1.378, up 2.38%, on 621,694 volume with 454 trades. The average volume for the last 60 days is 724,288 and the stock's 52-week low/high is $0.60/$7.60.

Chilean Metals, Inc. (CMETF)

MarketWatch, OTC Markets, BayStreet.ca, 4-Traders, Stockhouse, Barchart, Junior Mining Network, Investors Hangout, Stockwatch, Investing News, Marketwired, The Street, The Wall Street Review, and Stock Daily Review reported on Chilean Metals, Inc. (CMETF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A mining exploration enterprise, Chilean Metals, Inc. is actively drilling large potential mineral deposits. The Company centers on the exploration for copper and gold in Chile and the Province of Nova Scotia. Chilean Metals is working to leverage its significant land position in Chile. It is also working to discover and develop Copper Gold deposits in Chile’s under-explored, easily accessible, low-elevation coastal belt. Chilean Metals lists on the OTC Markets Group’s OTCQB. The Company is based in Toronto, Ontario.

Chilean Metals is also working to acquire interests in prospective properties without underlying third party royalties or interests. In addition, the Company’s focus is to receive cash flow from its ownership of a 3 percent net smelter return (NSR) royalty on future production from the Copaquire Cu-Mo deposit of Teck Resources Limited.

Chilean Metals Chile projects comprise Zulema, the contiguous Palo Negro and Hornitos properties, the Tierra de Oro (TDO) property, as well as the above-mentioned Copaquire property Royalty. In Nova Scotia, the Company’s projects comprise Bass River, Fox River, Parrsboro, and Lynn.

The Zulema project consists of 4,300 hectares (10,600 acres) in the core of the productive Atacama mineral belt in Chile’s 3rd Region. The contiguous Palo Negro and Hornitos properties are 100 percent owned by Chilean Metals. Together they consist of greater than 9,000 hectares (23,000 acres) in the Atacama Province of Chile’s Third Region.

The Company’s wholly-owned Tierra de Oro (TDO) property is situated in Chile’s prolific IOCG (iron oxide-copper-gold) belt. The 5,600 hectare (14,000 acre) property is 70 kms south of the mining town of Copiapo in Chile’s Third Region.

Regarding the Copaquire Cu-Mo deposit of Teck Resources Limited, it has two 43-101-compliant resources. One is Sulfato South (dominantly copper). The other is Cerro Moly (dominantly molybdenum).

The Bass River project is in central Nova Scotia. It consists of 4 licenses totaling 196 claims. The Fox River property consists of 61 claims. It is situated adjacent to, and due north of, the town of Port Grenville, Nova Scotia.

The Parrsboro property in Nova Scotia consists of 32 claims, positioned roughly 4 km north of the town of Parrsboro and east and south of Jeffers Lake. The Lynn property comprises 121 claims encompassing the east portion of Minotaur gravity anomalies NS06 and NS07. These claim blocks are 3.5 km north of the town of Moose River and all the claims are held by Chilean Metals.

The Chilean Metals /Highlander JV initiated a Drill Phase at Bass River N. A

large target was confirmed – 540m x 476m. Chilean Metals and Highlander Resources Corp. announced last month the completion of Minotaur Exploration Ltd.’s (Australia) analysis of the ground Pulse Electro-Magnetic (PEM) data collected by Clearview Geophysics Ltd. in December. The results were very positive, Maxwell plate modeling delineating a target of substantial strike length and depth.

Chilean Metals, Inc. (CMETF), closed Tuesday's trading session at $0.06, up 20.00%, on 100 volume with 1 trade. The average volume for the last 60 days is 17,701 and the stock's 52-week low/high is $0.0399/$0.2383.

Bionik Laboratories Corp. (BNKL)

MarketWatch, Stockhouse, and OTC Markets reported on Bionik Laboratories Corp. (BNKL), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Bionik Laboratories Corp. is a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home. Through the acquisition of Interactive Motion Technologies, the Company has added a portfolio of products centered on upper and lower extremity rehabilitation of stroke patients. It fully integrated Interactive Motion Technologies, Inc. into the Company following the May 2016 acquisition.

Bionik Laboratories lists on the OTC Markets Group’s OTCQB. Established in 2010, the Company is based in Toronto, Ontario.

Bionik Laboratories has three products available on the market and three products in different stages of development. The design of the InMotion Systems - the InMotion ARM™, InMotion WRIST™, InMotion HAND™ and InMotion ANKLE™, are to provide intelligent, patient-adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery.

The InMotion ARM is an evidence based intelligent, interactive rehabilitation technology. It senses patient movements and limitations, providing assistance-as-needed™ in real-time.

The InMotion HAND is an add-on module to be used with the InMotion ARM™. These two work in tandem to provide assist-as-needed™ support for reaching with grasp and release movements, or independently for focused training on individual hand movements.

The InMotion WRIST is an evidence based and research proven interactive rehabilitation device. InMotion WRIST senses patient movements and limitations. Moreover, it provides assistance-as-needed™. It can accommodate the range of motion of a normal wrist in daily tasks. InMotion WRIST can be used by clinicians as a stand-alone treatment option or in addition to the InMotion ARM.

Bionik Laboratories is also developing a lower-body exoskeleton, ARKE™. The design of ARKE™ is to allow paraplegics and other wheelchair users the ability to rehabilitate via walking.

Yesterday, Bionik Laboratories announced the launch of its improved InMotion Arm interactive robotic system for clinical rehabilitation of stroke survivors and those with mobility impairments because of neurological conditions. The improved new generation InMotion Arm will provide the same unique active-assisted robotic therapy. It will do so however with a new industrial design, which is modern, smaller, as well as sleeker. The software interface was completely redesigned to permit greater ease of use and as a result decreased training requirements for clinical staff.

Bionik has already sold and placed units of its new generation InMotion Arm system with rehabilitation hospitals. These include Saint Luke's South Hospital in Overland Park, Kansas and Bacharach Institute for Rehabilitation in Pomona, New Jersey.

Bionik Laboratories Corp. (BNKL), closed Tuesday's trading session at $0.14, up 6.06%, on 39,946 volume with 10 trades. The average volume for the last 60 days is 28,622 and the stock's 52-week low/high is $0.10/$1.48.

Jerrick Media Holdings, Inc. (JMDA)

CFN Media Group and MassiveStockProfits reported previously on Jerrick Media Holdings, Inc. (JMDA), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Jerrick Media Holdings, Inc. is a digital media and technology company. It focuses on the development and marketing of branded digital content and e-commerce properties. The Company produces and distributes premier digital media across numerous platforms for many targeted demographics. Jerrick Media Holdings is headquartered in Englewood, New Jersey.

The Company’s brand portfolio is delivered by way of Vocal. This is its proprietary technology and content distribution platform. All verticals are overseen by the same team and ideology, concentrating chielfy on revenue conversion as the underpinning all published material.

Vocal is a unique platform. The Vocal platform hosts almost 30 niche-communities. These include science fiction, poetry, music, health and wellness, and pop culture. Vocal is a content distribution platform and publishing hub.

Vocal enables content creators to create rich user experiences. Vocal has a seamless integration between content and commerce. Vocal takes advantage of the power of specific and dedicated audiences with a developing content creation engine. It blends thought-provoking, appealing content with SEO (Search Engine Optimized) and monetization capabilities.

Verticals on Vocal include Beat - the guiding track to all things music;
Feast – a celebration of food; and Geeks, which focuses on the storied worlds of comic cons, video games, movies, comic books, as well as television.

Additionally, Verticals include Journal, which emphasizes everything work-related; Filthy, which delves into the world of sexuality; and Longevity, which presents the new frontiers of health and wellness.

Furthermore, Jerrick Media has its Wander and Humans verticals. Wander is a community created for travelers. Humans is all about relationships and caters to those who identify as single, married, or other.

Jerrick Media is expanding its revenue opportunities (and those of its content creators) through leveraging the Jerrick library of assets through partnerships with celebrity thought-leaders and influencers. Subsequent to the Company’s April 2017 announcement of its collaboration with Maven Pictures to produce a scripted television series, Jerrick entered into a deal with actor, Jared Leto (Suicide Squad, Dallas Buyers Club, Blade Runner) to create original content in combination with Jerrick's Omni Magazine.

In November 2017, Jerrick Media announced that it added two new social publishing communities to its Vocal platform. Blush is for all things beauty, and Cleats is for all things soccer/football.

At the end of November, Jerrick Media announced, on the one year anniversary of the product's launch, that its social publishing platform Vocal crossed more than 100,000 user (content creator) accounts. It is reaching more than 5,000,000 page views monthly. The Company is on course to double its creator base by the end of Q1 2018.

Last month, Jerrick Media announced that it entered into material discussions with Thinkmill that may or may not result in a joint venture (JV), or another form of partnership involving a significant transaction. Thinkmill is a digital development company headquartered in Sydney, Australia.

Mr. Jeremy Frommer, Jerrick Media Holdings’ Chief Executive Officer, said, "We've spent over three years working closely with Thinkmill and they are world class developers. Given the exponential success of Vocal, the platform we built together, a broader relationship between the two companies makes perfect sense."

Jerrick Media Holdings, Inc. (JMDA), closed Tuesday's trading session at $0.22, up 10.00%, on 12,320 volume with 7 trades. The average volume for the last 60 days is 30,256 and the stock's 52-week low/high is $0.052/$0.31.

Kootenay Zinc Corp. (KTNND)

Stockhouse, MarketWatch, Morningstar, TradingView, OTC Markets, Investing, InterActiveBrokers.com, and Investors Hangout reported on Kootenay Zinc Corp. (KTNND), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A mineral exploration and development company, Kootenay Zinc Corp. engages in the exploration and development of mineral properties in Canada. It engages in the exploration and advancement of the Sully property, situated in Kootenay, British Columbia (B.C).

The Company previously went by the name Oceanside Capital Corp. It changed its name to Kootenay Zinc Corp. in October of 2016. The Company is headquartered in Vancouver, British Columbia. Kootenay Zinc’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s emphasis is on discovering large-scale sedimentary-exhalative (SEDEX) deposits. The Sully Property is situated roughly 30 kilometers east of
Kimberley, B.C. It consists of 1,375 hectares.

The Sully Project is positioned near Fort Steele, B.C., 30 kilometers east of the past-producing Sullivan mine of Teck Resources. The Sullivan Mine of Teck Resources was one of the world’s largest SEDEX silver, lead, zinc deposits.

This past November, Kootenay Zinc announced that it entered into an amendment agreement with Gravitas Metals Corp. and the shareholders of Gravitas dated effective October 20, 2017 regarding the option agreement with
Gravitas and the Gravitas Vendors dated effective September 30, 2016.

Kootenay Zinc has the option to acquire all the issued and outstanding shares of Gravitas that pursuant to an option agreement between Gravitas and the holders of the certain mining claims (the Sully Vendors) in the Fort
Steele Mining Division in the southeast portion of B.C (the Sully Property) dated October 21, 2011, as amended, holds an exclusive
option (the Sully Property Option) and right to acquire an 80 percent interest in the Sully Property.

With this Amended Agreement, Kootenay and Gravitas amended the terms of the Agreement to align with an amendment of the terms of the Underlying Sully Property Agreement. To maintain the Option in good standing Kootenay was required to issue to the Sully Vendors 80,000 common shares on or before October 21, 2017; and pay to the Sully Vendors $200,000 on or before April 21, 2018 (instead of on or before October 21, 2017), in cash, common shares of Kootenay, certified check or wire transfer.

If Kootenay satisfies the terms and properly exercises the Option, and receives all the issued and outstanding shares of Gravitas, Gravitas will become a wholly-owned subsidiary of Kootenay. With the Underlying Sully Property Agreement, the Company will hold 80 percent indirect, legal and beneficial interest in and to the Sully Property.

Last week, Kootenay Zinc announced that it closed the initial tranche of the non-brokered private placement for 4,500,000 units for gross proceeds $1,215,000 at a price of $0.27 per unit. Each unit consists of one common share of the Company and one common share purchase warrant. The proceeds of the private placement will be used for Kootenay Zinc’s exploration activities and general working capital.

Kootenay Zinc Corp. (KTNND), closed Tuesday's trading session at $0.4036, up 34.62%, on 1,659,627 volume with 1,416 trades. The average volume for the last 60 days is 531 and the stock's 52-week low/high is $0.07/$5.90.

MYM Nutraceuticals, Inc. (MYMMF)

OTC Markets, Barchart, Stockhouse, MarketWatch, InvestorsHub, Investing, and Market News Updates reported on MYM Nutraceuticals, Inc. (MYMMF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, MYM Nutraceuticals, Inc. concentrates on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. The Company is looking to acquire complementary businesses and assets in the technology, nutraceuticals, as well as CBD sectors. MYM is the sole owner of CBD brands HempMed, Joshua Tree, and Dr. Furbaby. MYM Nutraceuticals has its corporate office in Vancouver, British Columbia.

Joshua Tree is targeted for the mainstream health market. Dr. Furbaby is the Company’s CBD line of products specifically for pets. HempMed is targeted at the dispensary market.

At present, MYM Nutraceuticals is constructing three large-scale production facilities in Canada and Australia. These are the Weedon Project; the Laval Project; and the Northern Rivers Project. Upon completion, the total amount of greenhouse growing space will surpass 2.7 million square feet.

The Weedon Project is in Weedon, Quebec. The Project will include a cannabis museum and a cannabis university for industry training. The Weedon Project has 1.5 million sq. ft. of greenhouse.

The Laval Project facility (Laval, Quebec) is 10,000 sq. ft. It will undergo expansion to 26,000 sq. ft. by 2019. The estimation is that the Laval Project will generate sales of $20 million by 2019.

The Northern Rivers Project (Casino, New South Wales, Australia) is a 1.2 million sq. ft. greenhouse project. The first crop is expected to be planted in Q4 2018. The Northern Rivers Project facility is believed to be the Southern Hemisphere's largest purpose-built greenhouse, designed specifically to produce medical-grade cannabis.

Furthermore, MYM Nutraceuticals has its MJT Manufacturing Project (Toronto, Ontario). The 5,000 sq. ft. production facility is a GMP certified, state-of-the-art extraction lab and production facility dedicated to industrial hemp processing (CBD).

The MYM Australia Project has filed for a Medical Research License in collaboration with Western Sydney University. MYM Nutraceuticals announced this week that PUF Ventures Australia (PVA) filed an application with the Australian Office of Drug Control for a medicinal cannabis license and a cannabis research license in collaboration with The National Institute of Complementary Medicine (NICM). NICM is an Australian Health Research Institute based at Western Sydney University in New South Wales.

MYM Nutraceuticals, Inc. (MYMMF), closed Tuesday's trading session at $2.15, up 13.76%, on 485,822 volume with 577 trades. The average volume for the last 60 days is 833,791 and the stock's 52-week low/high is $0.1296/$4.00.


The QualityStocks
Company Corner


Epazz, Inc. (EPAZ)

The QualityStocks Daily Newsletter would like to spotlight Epazz, Inc. (EPAZ). Today, Epazz, Inc. closed trading at $0.105, up 25.00%, on 750,124 volume with 102 trades. The stock’s average daily volume over the past 60 days is 940,911, and its 52-week low/high is $0.0045/$0.52.

Blockchain has heralded innovation, stretching across both the financial and technological worlds, which has paved the way for new methods of online transaction. The underlying blockchain technology is one such method that not only protects the anonymity of users during transactions, but also allows for the securing of transaction contents. With the digital age bringing many questions revolving around online transactions companies such as Epazz, Inc. (EPAZ) and others are gaining increasing attention from investors.

Epazz, Inc. (EPAZ), is a leading provider of blockchain cryptocurrency mobile apps and cloud-based business software solutions that specializes in providing customized web applications to the corporate world, higher education institutions and the public sector. The company's strategic expansion into the investment fintech software space can be seen in the recent acquisition of the android app CryptoFolio, which securely tracks and manages Bitcoin and Altcoin portfolios. Epazz, Inc., which acquired the software rights, source code and user base of CryptoFolio, plans to add additional cryptocurrencies and languages to the app, along with an iOS version to attract more users.

Epazz also offers ZenaPay Bitcoin wallet, which has been downloaded more than 10,000 times since its launch on the Play Store. A subsidiary of Epazz, ZenaPay is a financial technology company that offers a unique, secure and reliable Bitcoin payment app, allowing consumers to acquire Bitcoin at the point-of-sale. The consumer can then use this digital currency to make a purchase with ease. The CryptoFolio business model provides free features to attract users and then allows users to purchase additional features from $1.99 to $5.99 each. CryptoFolio is a great add-on app for ZenaPay, and future versions of CryptoFolio will include an option to download ZenaPay.

"We are starting 2018 with ZenaPay on both major mobile apps' platforms," said Shaun Passley, PhD, CEO and founder of Epazz. "We are in the processing of developing new blockchain technology which will introduce an additional source of revenue streams for our company."

Epazz technology makes it easy to convert legacy systems into cloud business process software, for which the company then charges an annual subscription fee. Epazz has acquired 11 software companies that have converted or are in the process of converting their legacy software products to cloud software using Epazz technology. Epazz then markets the new cloud-based solutions to new and existing customers.

Epazz's unique BoxesOS™ applications can create virtual communities for enhanced communication, provide information and content for decision-making, and create a secure marketplace for any type of commerce. Epazz has also filed a provisional patent for its new blockchain smart legal contract technology that reduces fraud in business transactional contracts. The technology allows for a transactional contract to become a living contract that is tracked and traced; it also verifies that a section of terms within a contract are followed and that all parties of an agreement obey the terms of the contract.

"Blockchain-based technology is the future of the Internet," Passley said. "Epazz will add blockchain technology to all of our products in the coming months using our blockchain cloud platform, BoxesOS. The company has been working with customers to understand the best uses of blockchain, and we are excited about filing the first of many blockchain patents, with many more to come." Disclaimer

Epazz, Inc. Company Blog

Epazz, Inc. News:

Blockchain Innovations Create New Synergies

Epazz Acquires Bitcoin Charts IOS App for Live Trading Data as Zenapay Wallet App Gains More Than 17,000 Downloads in January

Epazz, Inc. (EPAZ) is “One to Watch”

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0708, up 22.28%, on 16,227,471 volume with 887 trades. The stock’s average daily volume over the past 60 days is 13,989,366, and its 52-week low/high is $0.0132/$0.415.

SinglePoint Inc. (OTCQB:SING), is pleased to announce it has been approved and is now trading on the OTCQB Venture Market, which requires a higher level of transparency and helps provide increased investor confidence through continued verification of information. Uplisting from the OTC Pink Open Market tier supports with the Company’s goals of increasing acquisition deal flow and having access to institutional investors both directly and through the open market.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

SinglePoint Begins Trading on the OTCQB Venture Market

NetworkNewsBreaks – SinglePoint, Inc.’s (SING) SingleSeed Payment Platform to Solve Cannabis Industry Banking Issues

SinglePoint Featured on MoneyTV with Donald Baillargeon, 2/2

First Cobalt Corp. (TSX.V:FCC) (OTCQB:FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF). Today, First Cobalt Corp. closed trading at $0.820745, up 13.27%, on 305,225 volume with 249 trades. The stock’s average daily volume over the past 60 days is 291,960, and its 52-week low/high is $0.3148/$1.3041.

First Cobalt Corp. (OTC: FTSSF) (TSX-V: FCC) was highlighted today in a report detailing that as of February 2, 2018, the cobalt spot price was $36.63, rising again strongly from just over $34 in early last month. In the past two months cobalt continues to rally up over 30%. The last few months in 2018 saw many of the electric vehicle (EV) companies and EV metal miners stock prices surge.

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

First Cobalt Corp. Company Blog

First Cobalt Corp. News:

Electric Vehicles (EV) and Niche Metals Demand Fueling Positive Outlook for Cobalt and Lithium Mining Industry

First Cobalt Intersects Broad Cobalt Mineralization at the Keeley Mine

Canadian Silver Hunter Inc. Reports 25 Metres of Mineralization Intersected at Keeley Mine

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $1.38, up 15.00%, on 428,855 volume with 785 trades. The stock’s average daily volume over the past 60 days is 507,874 and its 52-week low/high is $0.27/$2.54.

Lexaria Bioscience (CSE:LXX) (OTCQB:LXRP) recently entered an agreement with a cannabis-infused edibles manufacturer, Cannfections Group Inc. The agreement is expected to generate new cannabis-based edible products using Lexaria’s patented DehydraTECH™ delivery technology. Also today, Lexaria was highlighted in a report from NetworkNewsWire explaining that, with the expected legalization of recreational cannabis use in Canada just months away, the Canadian cannabis industry is experiencing a frenzied flow of capital that is only likely to accelerate. While this capital rush won’t affect every company in the space, the overriding sentiment supports global aspirations and trickle-down opportunity for innovators like Lexaria.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Agreement to Create Cannabis-infused Edibles Utilizing DehydraTECH™ Delivery Technology

Cannabis Deals Cross the Billion-Dollar Mark in Canada

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Agreement with Cannabis-Infused Edibles Manufacturer

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $1.1523, up 7.68%, on 67,986 volume with 51 trades. The stock’s average daily volume over the past 60 days is 137,584 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (ORHB) announced today that $3.2 million dollars has been successfully raised to further the Company’s reach into the marketplace with its revolutionary healthcare IT Vertical Specific Software, which is poised to transform the business of surgery by delivering real-time, case-based surgical data analytics.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub Raises Additional $3 Million to Fund Swift Strategic Market Penetration

ORHub Raises $3.8 Million Through Successful Warrant Exercise

ORHub, Inc. Sponsors DOCSF18: Digital Orthopedics Conference Hosted by UCSF

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.029, off by 3.33%, on 12,712,938 volume with 295 trades. The stock’s average daily volume over the past 60 days is 15,346,503, and its 52-week low/high is $0.009/$0.16.

Global Payout, Inc. (GOHE) ("Global") is pleased to announce that its majority owned subsidiary, MoneyTrac Technology, Inc. ("MTRAC", the "Company"), has executed a Sales Partnership and Commission Agreement with Eyeconic.tv ("Eyeconic.tv"), an award winning and leading retail technology company that operates a cannabis media network, the Eyechronic network, that has already successfully partnered with almost 300 medical and retail dispensaries throughout the U.S.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

MoneyTrac Technology, Inc. Bolsters Advertisement Solutions for Cannabis Industry Through Sales Partnership Agreement with Eyeconic.TV

Global Payout, Inc. Announces Fintech Veteran Joining its Supply Chain Finance Subsidiary SecurCapital Corp

CannabisNewsAudio Announces Audio Press Release (APR) on Profit Potential Amid Cannabis and Blockchain Market Frenzy


The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO). Today, EVIO, Inc. closed trading at $1.49, off by 5.10%, on 111,312 volume with 129 trades. The stock’s average daily volume over the past 60 days is 116,872, and its 52-week low/high is $0.47/$2.70.

EVIO, Inc. (OTCQB: EVIO) was featured today in a report explaining that the regulatory uncertainties surrounding cannabis will have little impact on the long-term growth of the industry. And that the company is the established national leader in such testing and verification, providing accredited cannabis testing, as well as high-quality analytical and consulting services for agricultural and biomedical industries in the United States.

EVIO, Inc. (EVIO), via the EVIO Labs division, is the nation's leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation's cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation's leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today's fastest growing industry. Disclaimer

EVIO, Inc. Company Blog

EVIO, Inc. News:

EVIO, Inc. (EVIO) is Exceeding Expectations

NetworkNewsBreaks – EVIO, Inc. (EVIO) Secures Over $5.9M in New Financing to Fund Expansion

EVIO, Inc. (EVIO) Provides a Critical Service to the Regulated Cannabis Industry

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF). Today, PreveCeutical Medical Inc. closed trading at $0.3486, off by 12.85%, on 15,500 volume with 11 trades. The stock’s average daily volume over the past 60 days is 6,971, and its 52-week low/high is $0.01/$0.80.

PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FRANKFURT:18H) announced today that it has engaged the corporate communications expertise of NetworkNewsWire ("NNW"). NNW is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services.

PreveCeutical Medical Inc. (PRVCF), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word "PreveCeutical" – a combination of the words "preventive" and "pharmaceutical" – was a precursor to the company's formation and incorporation in October 2015.

The company's first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical's research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical's gene-silencing technology would effectively "turn off" the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical's science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland's (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.'s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company's core. Disclaimer

PreveCeutical Medical Inc. Company Blog

PreveCeutical Medical Inc. News:

PreveCeutical Medical Inc. (PRVCF) Engages NetworkNewsWire for Corporate Communications Solutions

NetworkNewsAudio Announces Audio Press Release (APR) on Exciting New Solutions to Tackle Pain

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Developing Alternative Solutions in Health-Boosting Market

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.492, off by 3.61%, on 8,074,057 volume with 2,017 trades. The stock’s average daily volume over the past 60 days is 12,580,244, and its 52-week low/high is $0.0006/$0.957.

A recent comprehensive report by SeeThruEquity highlighting PotNetwork Holding Inc. (OTC: POTN) and its subsidiary, Diamond CBD, projected a heightened share price target set at $1.25. The increase was attributed to the company’s strong monthly sales data and 3Q17 filings (http://cnw.fm/A2krk). Per the report, these indicated “continued profitability as the company invests in growth.”

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

Recent Report on PotNetwork Holding Inc. (POTN) Share Price Target Highlights Encouraging Data

Diamond CBD Inc. Exhibits in Las Vegas at the Tobacco Plus Expo on January 30 - February 1

SeeThruEquity Heightens Share Price Target to $1.25 on PotNetwork Holding in Updated Research Report


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Penny Stock Titans
(CLKA) +69.23%


(NXCN) +49.25%


(ASFI) +43.36%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251